C4 Therapeutics Positions Cemsidomide As Potential Best-In-Class Myeloma Therapy While Expanding Discovery Efforts Beyond Oncology
Benzinga Newsdesk 9 months ago
News
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µgCemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026Internal Discovery
- Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg
- Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026
- Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways
- Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points